Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial (SATIE)

Carmen Olmos, Isidre Vilacosta, Javier López, Carmen Sáez, Manuel Anguita, Pablo Elpidio García-Granja, Cristina Sarriá, Jacobo Silva, Belén Álvarez-Álvarez, María Amparo Martínez-Monzonis, Juan Carlos Castillo, José Seijas, Amanda López-Picado, Vicente Peral, Luis Maroto, J Alberto San Román, Carmen Olmos, Isidre Vilacosta, Javier López, Carmen Sáez, Manuel Anguita, Pablo Elpidio García-Granja, Cristina Sarriá, Jacobo Silva, Belén Álvarez-Álvarez, María Amparo Martínez-Monzonis, Juan Carlos Castillo, José Seijas, Amanda López-Picado, Vicente Peral, Luis Maroto, J Alberto San Román

Abstract

Background: Most serious complications of infective endocarditis (IE) appear in the so-called "critical phase" of the disease, which represents the first days after diagnosis. The majority of patients overcoming the acute phase has a favorable outcome, yet they remain hospitalized for a long period of time mainly to complete antibiotic therapy. The major hypothesis of this trial is that in patients with clinically stable IE and adequate response to antibiotic treatment, without signs of persistent infection, periannular complications or metastatic foci, a shorter antibiotic time period would be as efficient and safe as the classic 4 to 6 weeks antibiotic regimen.

Methods: Multicenter, prospective, randomized, controlled open-label, phase IV clinical trial with a non-inferiority design to evaluate the efficacy of a short course (2 weeks) of parenteral antibiotic therapy compared with conventional antibiotic therapy (4-6 weeks).

Sample: patients with IE caused by gram-positive cocci, having received at least 10 days of conventional antibiotic treatment, and at least 7 days after surgery when indicated, without clinical, analytical, microbiological or echocardiographic signs of persistent infection. Estimated sample size: 298 patients.

Intervention: Control group: standard duration antibiotic therapy, (4 to 6 weeks) according to ESC guidelines recommendations. Experimental group: short-course antibiotic therapy for 2 weeks. The incidence of the primary composite endpoint of all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the inclusion in the study will be prospectively registered and compared.

Conclusions: SATIE will investigate whether a two weeks short-course of intravenous antibiotics in patients with IE caused by gram-positive cocci, without signs of persistent infection, is not inferior in safety and efficacy to conventional antibiotic treatment (4-6 weeks).

Trial registration: ClinicalTrials.gov Identifier: NCT04222257 (January 7, 2020). EudraCT 2019-003358-10.

Keywords: Antibiotic therapy; Infective endocarditis; Short-course.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Tleyjeh IM, Bin Abdulhak AA. Epidemiology and global burden of infective endocarditis. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW, editors. ESC CardioMed. 3th ed. Oxford: Oxford University press; 2018. European Society of Cardiology.
    1. Olmos C, Vilacosta I, Fernández-Pérez C, Bernal JL, Ferrera C, García-Arribas D, Pérez-García CN, San Román JA, Maroto L, Macaya C, Elola FJ. The evolving nature of infective endocarditis in Spain: a population-based study. J Am Coll Cardiol. 2017;70:2795–2804. doi: 10.1016/j.jacc.2017.10.005.
    1. Sevilla T, López J, Gómez I, Vilacosta I, Sarriá C, García-Granja PE, Olmos C, Di Stefano S, Maroto L, San Román JA. Evolution of prognosis in left-sided infective endocarditis: a propensity score analysis of 2 decades. J Am Coll Cardiol. 2017;69:111–112. doi: 10.1016/j.jacc.2016.10.052.
    1. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, Doco-Lecompte T, Celard M, Poyart C, Strady C, Chirouze C, Bes M, Cambau E, Iung B, Selton-Suty C, Hoen B, AEPEI Study Group Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968–1976. doi: 10.1016/j.jacc.2012.02.029.
    1. Chirouze C, Athan C, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, Erpelding ML, Miro JM, Olaison L, Hoen B, International Collaboration on Endocarditis Study Group Enterococcal endocarditis in the beginning of the 21st century:analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013;19:1140–1147. doi: 10.1111/1469-0691.12166.
    1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) Eur Heart J. 2015;36:3075–3128. doi: 10.1093/eurheartj/ehv319.
    1. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, Høfsten DE, Fursted K, Christensen JJ, Schultz M, Klein CF, Fosbøll EL, Rosenvinge F, Schønheyder HC, Køber L, Torp-Pedersen C, Helweg-Larsen J, Tønder N, Moser C, Bundgaard H. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–424. doi: 10.1056/NEJMoa1808312.
    1. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis. 1995;21:1406–1410. doi: 10.1093/clinids/21.6.1406.
    1. Ribera E, Gómez-Jiménez J, Cortés E, del Valle O, Planes A, González-Alujas T, Almirante B, Ocaña I, Pahissa A. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med. 1996;125:969–74.
    1. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med. 2009;169:463–473. doi: 10.1001/archinternmed.2008.603.
    1. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG, Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, Verhagen DW, Cabell CH. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE prospective cohort study (ICE-PCS) Am Heart J. 2007;154:1086–1094. doi: 10.1016/j.ahj.2007.07.023.
    1. Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ, Woods CW, Reller LB, Ryan T, Fowler VG., Jr Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002;162:90–94. doi: 10.1001/archinte.162.1.90.
    1. Morris AJ, Drinković D, Pottumarthy S, MacCulloch D, Kerr AR, West T. Bacteriological outcome after valve surgery of active infective endocarditis: implications for duration of treatment after surgery. Clin Infect Dis. 2005;41:187–194. doi: 10.1086/430908.
    1. Muñoz P, Giannella M, Scoti F, Predomingo M, Puga D, Pinto A, Roda J, Marin M, Bouza E. Two weeks of postsurgical therapy may be enough for high-risk cases of endocarditis caused by Streptococcus viridans or Streptococcus bovis. Clin Microbiol Infect. 2012;18:293–299. doi: 10.1111/j.1469-0691.2011.03594.x.
    1. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011;15:R267. doi: 10.1186/cc10545.
    1. Petite SE, Nguyen K. Evaluation of antimicrobial therapy duration for hospital-acquired pneumonia treatment. Infect Dis Clin Pract. 2018;26:87–90. doi: 10.1097/IPC.0000000000000577.
    1. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–2598. doi: 10.1001/jama.290.19.2588.
    1. Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T, Roch A, Faisy C, Cousson J, Limat S, Mercier M, Papazian L. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One. 2012;7:e41290. doi: 10.1371/journal.pone.0041290.
    1. Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child. 2002;87:118–123. doi: 10.1136/adc.87.2.118.
    1. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–S31. doi: 10.1086/521859.
    1. Heiro M, Helenius H, Hurme S, Savunen T, Metsärinne K, Engblom E, Nikoskelainen J, Kotilainen P. Long-term outcome of infective endocarditis: a study on patients surviving over one year after the initial episode treated in a Finnish teaching hospital during 25 years. BMC Infect Dis. 2008;8:49. doi: 10.1186/1471-2334-8-49.
    1. Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, Olmos C, Sáez C, López J, Sarriá C, Pérez-García CN, García-Arribas D, Ciudad M, García-Granja PE, Ladrón R, Ferrera C, Di Stefano S, Maroto L, Carnero M, San Román JA. Contemporary epidemiology and outcomes in recurrent infective endocarditis. Heart. 2019. pii: heartjnl-2019–315433. doi: 10.1136/heartjnl-2019-315433. [Epub ahead of print].

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다